Osteoporosis Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2025-2035

Market Overview:

The osteoporosis market reached a value of USD 10.5 Billion across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 15.4 Billion by 2035, exhibiting a growth rate (CAGR) of 3.35% during 2025-2035.

The osteoporosis market has been comprehensively analyzed in IMARC's new report titled "Osteoporosis Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2025-2035". Osteoporosis refers to a medical condition characterized by the loss of bone mass and degeneration of bone tissue, resulting in weakened and fragile bones. Some of the common symptoms of the disorder include a stooped or hunched posture (kyphosis), a gradual loss of height, fractures that occur with minimal trauma or even normal daily activities, etc. Individuals with osteoporosis may also experience back pain, bone tenderness, and a decreased ability to perform physical activities. For disease diagnosis, the healthcare providers review the patient's medical history, family history of osteoporosis, and risk factors, such as age, gender, medication use, etc. A physical examination may reveal signs of bone loss or previous fractures. Various diagnostic procedures, including dual-energy X-ray absorptiometry (DXA) scans that measure bone mineral density and help in assessing the severity of osteoporosis, are also utilized. Additionally, blood tests may be conducted to evaluate calcium levels, vitamin D levels, and other markers of bone health.

The increasing cases of age-related bone loss, in which the rate of bone formation tends to slow down while bone resorption continues, thereby leading to a gradual decline in bone density over time, are primarily driving the osteoporosis market. In addition to this, the rising prevalence of numerous associated risk factors, such as genetic predisposition, lack of physical activity, hormonal imbalances, long-term use of certain medications like corticosteroids, etc., is also augmenting the market growth. Furthermore, the widespread adoption of bisphosphonates, including alendronate and risedronate, to slow down bone loss and reduce fracture risk in patients is acting as another significant growth-inducing factor. Besides this, various key players are making extensive investments in R&D activities to introduce drugs that specifically target proteins involved in bone remodeling and signaling pathways. This, in turn, is creating a positive outlook for the market. Additionally, the ongoing advancements in imaging technologies, such as the launch of high-resolution peripheral quantitative computed tomography (HR-pQCT) and trabecular bone score (TBS), which offer new insights into bone microarchitecture and strength as well as help in assessing fracture risk more accurately, are expected to drive the osteoporosis market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the osteoporosis market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for osteoporosis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the osteoporosis market in any manner.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the osteoporosis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the osteoporosis market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current osteoporosis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the osteoporosis market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the osteoporosis across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the osteoporosis across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of prevalent cases (2019-2035) of osteoporosis across the seven major markets?
• What is the number of prevalent cases (2019-2035) of osteoporosis by age across the seven major markets?
• What is the number of prevalent cases (2019-2035) of osteoporosis by gender across the seven major markets?
• What is the number of prevalent cases (2019-2035) of osteoporosis by type across the seven major markets?
• How many patients are diagnosed (2019-2035) with osteoporosis across the seven major markets?
• What is the size of the osteoporosis patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2025-2035) across the seven major markets?
• What are the key factors driving the epidemiological trend osteoporosis of?
• What will be the growth rate of patients across the seven major markets?

Osteoporosis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for osteoporosis drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the osteoporosis market?
• What are the key regulatory events related to the osteoporosis market?
• What is the structure of clinical trial landscape by status related to the osteoporosis market?
• What is the structure of clinical trial landscape by phase related to the osteoporosis market?
• What is the structure of clinical trial landscape by route of administration related to the osteoporosis market?